
    
      This is a parallel group, active control, single-center, open-label, randomized controlled
      trial comparing the safety and efficacy of initial therapy with an angiotensin converting
      enzyme (ACE) inhibitor (lisinopril) vs. beta-blocker therapy (atenolol) each administered
      three times weekly after dialysis.
    
  